/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

VERA THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

VERA THERAPEUTICS INC share price today is $41.17, up -2.07%. The stock opened at $41.06 against the previous close of $42.04, with an intraday high of $41.56 and low of $39.68.

VERA THERAPEUTICS INC Share Price Chart

style
pb-0

VERA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

VERA THERAPEUTICS INC Share Price Performance

$41.17 -0.0207(-2.07%) VERA at 13 Mar 2026 03:44 PM Biotechnology
Lowest Today 39.68
Highest Today 41.56
Today’s Open 41.06
Prev. Close 42.04
52 Week High 56.05
52 Week Low 18.53
Day’s Range: Low 39.68 High 41.56
52-Week Range: Low 18.53 High 56.05
1 day return -
1 Week return +5.45
1 month return -2.62
3 month return -16.24
6 month return +69.81
1 year return +49.09
3 year return +459.51
5 year return +256.84
10 year return -

VERA THERAPEUTICS INC Institutional Holdings

venBio Select Advisor LLC 8.25

BlackRock Inc 5.95

Deerfield Management Co 5.69

T. Rowe Price Associates, Inc. 5.14

Vanguard Group Inc 5.00

Kynam Capital Management, LP 4.81

FMR Inc 4.04

Eversept Partners, LP 3.94

Sofinnova Ventures 3.92

State Street Corp 3.27

Vanguard Total Stock Mkt Idx Inv 2.64

Integral Health Asset Management, LLC 2.38

Bellevue Group AG 2.38

Citadel Advisors Llc 2.26

T. Rowe Price Health Sciences 2.02

State Street® SPDR® S&P® Biotech ETF 2.00

Pictet Asset Manangement SA 1.95

iShares Russell 2000 ETF 1.89

TANG CAPITAL MANAGEMENT LLC 1.89

Geode Capital Management, LLC 1.85

Holocene Advisors, LP 1.83

Point72 Asset Management, L.P. 1.78

Fidelity Growth Compy Commingled Pl S 1.68

Tri Locum Partners LP 1.67

US Small-Cap Growth II Equity Comp 1.59

T. Rowe Price New Horizons 1.59

Woodline Partners LP 1.40

Pictet-Biotech P USD 1.39

Fidelity Growth Company Fund 1.22

Vanguard Institutional Extnd Mkt Idx Tr 0.98

T. Rowe Price Integrated US SmCapGrEq 0.96

T. Rowe Price Integrated US Sm Gr Eq 0.96

International Biotechnology Ord 0.95

American Century Small Cap Growth Inv 0.79

American Century U.S. Small Cap Growth 0.79

Fidelity Small Cap Index 0.76

T. Rowe Price New Horizons Tr-A 0.71

iShares Russell 2000 Growth ETF 0.65

Candriam Eqs L Biotech C USD Cap 0.63

Pictet-Global Megatrend Sel I USD 0.59

VERA THERAPEUTICS INC Market Status

Strong Buy: 9

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

VERA THERAPEUTICS INC Fundamentals

Market Cap 2999.79 M

PB Ratio 4.9623

PE Ratio 0.0

Enterprise Value 2362.51 M

Total Assets 734.73 M

Volume 1227875

VERA THERAPEUTICS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-102774000 -102.8M, FY22:-89056000 -89.1M, FY21:-32609000 -32.6M, FY20:-53413000 -53.4M, FY19:-11854000 -11.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-564000 -0.6M, Q2/2025:-563000 -0.6M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-80293000 -80.3M, Q2/2025:-76531000 -76.5M, Q1/2025:-51694000 -51.7M, Q3/2024:-46632000 -46.6M, Q2/2024:-33708000 -33.7M

About VERA THERAPEUTICS INC & investment objective

Company Information Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Organisation Biotechnology

Employees 249

Industry Biotechnology

CEO Dr. Marshall W. Fordyce M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow